Biotech entity
Every one of those 2 sits in a single category, gene-therapy. Of the tracked stories, 2 of 2 also mention AMT-130, the most common co-covered peer. That works out to roughly 0.1 stories per week across a 156-day span. They are less corroborated than the beat average, carrying 2 original sources each against 3.7 for the same window.
Last mentioned: Aug 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, gene-therapy. Of the tracked stories, 2 of 2 also mention AMT-130, the most common co-covered peer. That works out to roughly 0.1 stories per week across a 156-day span. They are less corroborated than the beat average, carrying 2 original sources each against 3.7 for the same window. Their average consequence score of 5.5 runs below the beat's 6.2 for that window. We currently track 2 Biotech stories that mention AMT-260, published between March 3, 2026 and August 5, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 551 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AMT-260. Shared-story counts are live from our verified record — not editorial picks.
Four-Year Follow-Up Data from AMT-130 Pivotal Study
Durability of gene therapy effect expected to be reported, a key factor for regulatory decisions.
Regulatory Submissions for AMT-130 in Huntington's Disease (Planned)
uniQure aims to file for U.S. and U.K. approval in Q3 2026, targeting accelerated pathways.
AMT-260 Preliminary Data and AMT-191 Further Analyses
Six-month follow-up from the Phase I/IIa AMT-260 trial in epilepsy and new Fabry data presented.
FDA Type B Meeting
Planned follow-up meeting to define the Phase III pathway for AMT-130 in Huntington's disease.
Earnings Release
Company announces 2025 results and provides update on FDA Type A meeting.
Updated AMT-191 Phase I/II Data in Fabry Disease
Interim data demonstrate sustained enzyme activity and safety in Fabry disease patients.
AMT-260 Data
Clinical data expected from the Phase I/IIa study in refractory mesial temporal lobe epilepsy.
Fiscal Year End
uniQure closes 2025 with $622.5M in cash and equivalents.
Positive Topline Data for AMT-130 in Huntington's Disease
uniQure reports positive pivotal Phase I/II data, showing statistically significant improvements in disease markers.
uniQure's AMT-130 for Huntington's disease is on track for U.S. and U.K. regulatory filings in Q3 2026, following positive pivotal data. Pipeline updates for AMT-191 and AMT-260 in Fabry disease and epilepsy show a broadening gene therapy platform.
Source: rttnews.com · finanzen.ch
uniQure reported a robust $622.5 million cash position, extending its operational runway into late 2029. While clinical data for its Huntington’s disease candidate AMT-130 remains strong, the company is still seeking regulatory alignment with the FDA on a definitive Phase III pathway.
AMT-260 is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
